Despite the potential NKG2D ligand induction being diverse, with ligands displaying varying induction time/stability, intratumoral heterogeneity, and abundance, there is still the potential therapeutic benefit as the tumor becomes more recognized by the immune system. This evidence concerns the gene KLRK1 and neoplasm.